Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06001749 · ClinicalTrials.gov registry record · Phase 2
Psilocybin in Cancer Pain Study
A Phase 2 study of Advanced Cancer and Opioid-Related Disorders, sponsored by Yvan Beaussant, MD, MSci.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06001749 is a Phase 2 study of Advanced Cancer and Opioid-Related Disorders that is actively recruiting participants, run by Yvan Beaussant, MD, MSci. The registered enrollment target is 15 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06001749, a Phase 2 study of Advanced Cancer and Opioid-Related Disorders, is actively recruiting participants, sponsored by Yvan Beaussant, MD, MSci.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer. The name of the study intervention used in this research study is: Psilocybin (a tryptamine derivative)
Conditions Studied
Interventions
- DRUG Psilocybin
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-09-23 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06001749
The ClinicalTrials.gov registry entry for NCT06001749 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Yvan Beaussant, MD, MSci, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.
NCT06001749 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06001749 about?
NCT06001749 is a clinical study titled "Psilocybin in Cancer Pain Study". The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer. The name of the study intervention used in this research study is: Psilocybin (a tryptamine derivat...
What is the current status of trial NCT06001749?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2024-09-23. Estimated completion is 2026-12-31.
What conditions does trial NCT06001749 study?
This clinical trial studies the following conditions: Advanced Cancer, Opioid-Related Disorders, Pain Management, Advanced Cancers, Pain Management and Care.
What interventions are being tested in trial NCT06001749?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT06001749?
This trial is sponsored by Yvan Beaussant, MD, MSci, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06001749 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
Psilocybin Therapy in Advanced Cancer
RECRUITING · Phase 2
-
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
RECRUITING · Phase 2
-
Intrapleural Catheter Daily Versus Three Times a Week Drainage
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.